Cipla Ltd is set to invest ZAR 900 million in its wholly-owned subsidiary, Cipla Medpro South Africa Proprietary Ltd. The ...

Mumbai: Cipla has announced that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro ...

Cipla Ltd is one of the leading pharmaceutical companies in India ... Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1500 products across wide range of th... We ...

CMSA, is a wholly owned subsidiary of Cipla, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical ...

Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has ... Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and ...

Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 Cipla Q3 Net Profit Soars 49% to Rs 1,571 Crore Cipla's net profit surged 49% to Rs 1,571 crore in Q3 FY25, driven by strong revenue ...

However, a key risk for the company is the delay in approvals for niche products, which is holding back its growth potential in the medium term. “We expect CIPLA to deliver 18% YoY earnings ...

Fertilisers stocks were trading higher on Tuesday at 10:57AM Sikko Industries Ltd.(up 5.11%), Gujarat Narmada Valley ...

For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.

The Quarterly Results page of Cipla Ltd. presents the key result items, its comparison with the sector peers and its previous 5 Quarterly Results.

For the first nine months of FY25, Cipla's EBITDA margin stood at 26.9%, already above its full-year guidance of 24.5% to 25.5%.